A ladder, not a starting figure
Most sellers in this comparison publish one number and let a reader discover the rest at titration. Here every rung of the tablet ladder is printed, and so is every rung of the pen ladder, with the strengths each figure covers named beside it.
That matters more on an approved product than anywhere else, because the step between strengths is large and the dose a patient ends on is not the dose they start on. A reader can work out a year here before buying anything, which is the whole argument for a published ladder.
The seller also defines its own unit of a month in writing: a bottle of thirty tablets, a box of four pens, a box of one pen. Three different units, all stated. Comparing this row against a flat monthly seller means checking which unit each figure belongs to first.
Two of the four headline figures are an entry rate
The two pen cards quote a rate that applies to two fills, for patients new to the programme, and then steps up. The card does not say so; the footnote behind it does. This roster records the ongoing rate on the price row and the entry rate separately as an introductory offer, so neither can be mistaken for the other.
The tablet figures are different in kind. Those are the self-pay prices by dose, and the seller's own printed price guide agrees with the page rung for rung. Only the pen carries a countdown.
Eleven of the seventy-three sellers here carry a recorded introductory rate. What makes this one worth reading twice is that the same headline number appears on four cards for two different products, so a reader can easily carry a tablet figure over to a pen or the other way round.
The dispensing pharmacies are named, and they are not the manufacturer
The pages state twice which pharmacies fill a cash prescription, and both are separate businesses from the company whose name is on the drug. Twenty of the seventy-three sellers here name a dispensing or compounding pharmacy at all, so this is disclosure at the better end of the field.
Delivery is scoped differently for the two routes, and the difference is easy to miss: one is described as available for local pharmacy pickup with a savings offer, the other for pickup or home delivery. Confirm which applies to the product you want before assuming either.
Thirteen of the seventy-three sellers here publish brand-name prices and no compounded price, and this is one of them. Everything on offer is an FDA-approved finished drug with a national drug code printed for every strength.
Two warning letters, and one of them is about these drugs
Eight of the seventy-three sellers here carry a recorded FDA warning letter. A letter is a disclosure and not a finding of guilt, and this comparison does not score a company down for one. It is still a fact a reader is entitled to before paying.
The first, from September 2025, concerns a direct-to-consumer video about the two semaglutide brands this row sells. The agency's stated reasoning was that the video omitted a contraindication from the boxed warning and misrepresented the safety profile. That is the same drug line, on the same company, from the same year.
The second, from March 2026, arises from an inspection and concerns postmarketing adverse drug experience reporting requirements. The number, the date and a link to the agency's own text are on this row so the letters can be read directly rather than summarised.
What it does not publish
There is no list of states. What the pages carry instead is a territorial condition covering the United States and its territories, which answers a different question. Forty-one of the seventy-three sellers here publish no service area at all, so the silence is ordinary.
Twenty of the seventy-three sellers here say nothing either way about a membership or programme fee, and this is one of them. A word-bounded census across both pages read found no membership sentence in either direction, so this row records the absence rather than reading it as a denial.
Eligibility is conditioned rather than open: the pages state that a buyer must be uninsured or insured and choosing to self-pay, and that the medication must have been prescribed for an approved use in the product's own labeling. Both conditions sit outside the price and both can disqualify.
The pages also argue against compounded semaglutide in the manufacturer's own commercial interest. Those are its claims about a competing category, attributed to it, and nothing here treats them as an independent finding.
NovoCare Pharmacy's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (brand) | $149/moThe bottom rung of the tablet ladder, from the footnote the card's "Starting at $149 per month" points at: "Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. One month defined as 1 bottle of 30 tablets. Eligibility and restrictions apply." Delivery is scoped for the tablet: "Pricing is only available for local pharmacy pickup with a savings offer." | September 2026source |
| Semaglutide (brand) | $199/moThe second rung of the same published tablet ladder: "$199 per month for 4 mg". One month is the seller's own unit here — "One month defined as 1 bottle of 30 tablets" — and the figure is not the card headline, which quotes the bottom rung. | September 2026source |
| Semaglutide (brand) | $299/moThe top of the published tablet ladder: "$299 per month for 9 mg and 25 mg", one month being "1 bottle of 30 tablets". Two dose strengths share one figure, so titrating from 9 mg to 25 mg does not move the bill. | September 2026source |
| Semaglutide (brand) | $349/moThe ONGOING self-pay rate, from the footnote behind the card's "Starting at $199 per month": "Patients new to the Wegovy Savings Offer and NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg. Offer is for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg." One month is "1 box of 4 pens". The two-fill entry rate is recorded separately as an introductory offer. | September 2026source |
| Semaglutide (brand) | $399/moThe high-dose pen, priced above the rest of the pen ladder in the same footnote: "$399 per month for Wegovy HD (semaglutide) injection 7.2 mg". One month is "1 box of 4 pens", and the seller's own price guide prints the same figure. | September 2026source |
| Semaglutide (brand) | $149/moThe tablet card for the diabetes brand, quoted verbatim as "Starting at $149 per month" against the footnote "Self-pay pricing varies by dose ... One month defined as 1 bottle of 30 tablets." ⚠ Unlike the weight brand, this card's footnote does not print a rung for every strength, so the figure above is the starting rung and the rest of the ladder is unread rather than absent. | September 2026source |
| Semaglutide (brand) | $349/moThe ONGOING self-pay rate for the diabetes pen: "pay $199 for each month of 0.25 mg and 0.5 mg. Offer for 2 monthly fills through December 31, 2026 then $349 per month for Ozempic 0.25 mg, 0.5 mg or 1 mg". One month is "1 box of 1 Ozempic pen" — a different unit from the weight pen's box of four. | September 2026source |
| Semaglutide (brand) | $499/moThe top rung of the diabetes pen ladder, from the same footnote: "$499 per month for Ozempic 2 mg", one month being "1 box of 1 Ozempic pen". The step from 1 mg to 2 mg is the largest single jump on either ladder this seller publishes. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 73 providers reviewed here are paid partners today; the other 69 are not. See how this works.
See NovoCare Pharmacy's current price →Good fit if
- Readers who want an FDA-approved semaglutide at the manufacturer's own cash price, with every rung of the ladder published in advance.
- Buyers who intend to titrate up and want to know what the higher strengths cost before they start rather than after.
- People who want the dispensing pharmacy named, and who want to know that the company on the box is not the company filling the prescription.
- Anyone who wants the seller's own definition of a month printed beside the figure instead of assuming a calendar one.
Look elsewhere if
- Anyone comparing against a compounded rate. These are approved-product prices and they are a different order of number.
- Readers who need their state confirmed first. No coverage list is published anywhere.
- Buyers who cannot use the entry rate — new patients only, for two fills — and are looking at the pen headline as though it were the ongoing price.
- People who want a programme fee ruled in or out in writing before paying.
How this review was verified
- Read the pharmacy page and the eligibility page in a browser and audited every dollar element for computed opacity, visibility and a real laid-out rectangle before recording a figure.
- Recorded the ongoing rate on each pen row and the two-fill entry rate separately as an introductory offer, because the card quotes the entry rate and only the footnote states the expiry.
- Cross-checked the whole ladder against the seller's own printed price guide, which is face-dated and carries a document code, and found it agreed rung for rung.
- Excluded the insured copay figure printed in that guide. It belongs to a commercial-insurance savings card and is not a cash price.
- Word-bounded the membership census before recording an absence: an unbounded search for the word fee returns twenty hits on these pages, every one of them inside the words feel and feeling in the safety copy, and the correct count is zero.
- Censused both pages for a state list and for the phrase covering all fifty states, and found neither; what exists is a territorial condition, which is recorded verbatim instead.
- Searched the agency's published warning-letter record for the named company, 2017 to 2026, through both a static file and the live table with a positive and a negative control in every pass, and read every returned row rather than counting them. That search covers warning letters only; untitled letters are published separately and were not searched.
- Probed the host with a nonsense path at two different depths in the same run as the reading; both returned a genuine not-found page with a distinct body, so a page that resolves here is a page that exists.